A Phase 2 Study of Duvelisib Efficacy and Safety in Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Previously Treated With a Bruton's Tyrosine Kinase Inhibitor (BTKi)
Phase of Trial: Phase II
Latest Information Update: 24 Oct 2018
Price : $35 *
At a glance
- Drugs Duvelisib (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Acronyms BRIO
- Sponsors Verastem Oncology
- 12 Oct 2018 Status changed from recruiting to suspended due to reassessing corporate priorities.
- 31 Aug 2018 Biomarkers information updated
- 03 May 2018 According to a Verastem Oncology media release, Verastem changed its name to Verastem Oncology.